newsfilter
← Latest News
ACCESS Newswire·

Dermata Therapeutics, Inc. Reports Third Quarter 2021 Financial Results and Provides Corporate Update

- Announced positive topline results from DMT310 proof of concept (POC) study in mild-to-moderate psoriasis - - Closed upsized $18.0 million initial public offering (IPO) on Nasdaq Capital Market - - Topline results from DMT410 POC study in multiple ae